Scientists in China have developed a new way to mass-produce cancer-fighting immune cells – turning a single stem cell into millions of natural killer (NK) cells, including precision-targeted CAR variants. By engineering early-stage cord blood stem cells rather than mature NK cells, the team achieved dramatically higher yields with improved consistency, addressing long-standing bottlenecks in cell therapy manufacturing.
The approach uses a three-step process: expansion of CD34+ hematopoietic stem cells, differentiation via artificial organoid systems, and large-scale maturation. The result is striking – one stem cell can generate up to ~14 million NK cells or ~7.6 million CAR-engineered NK cells, with projections suggesting a single cord blood unit could supply thousands of therapeutic doses. Crucially, the method also reduces viral vector requirements for genetic engineering by up to ~600,000-fold, significantly lowering production costs.
In leukemia mouse models, the engineered CAR-NK cells effectively suppressed tumor growth and extended survival, matching or exceeding the performance of conventional NK approaches. The cells also retained potency after cryopreservation, supporting the prospect of “off-the-shelf” immunotherapies.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
